TY - JOUR
T1 - 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1β production
AU - Peleg, Sara
AU - Qiu, Haiyen
AU - Reddy, Saravathy
AU - Harris, David
AU - Van, Quin
AU - Estey, Elihu H.
AU - Talpaz, Moshe
AU - Estrov, Zeev
PY - 1997/10/1
Y1 - 1997/10/1
N2 - We hypothesized that 1,25-dihydroxyvitamin D3 (1,25D3) and its analogues may inhibit acute myelogenous leukemia (AML) proliferation by interrupting IL-1β-mediated growth-stimulatory signals. The incubation of the IL-1β-responsive AML cell line OCIM2 with 10 nM 1,25D3 reduced growth 80% in liquid culture, and a 100-1000-fold lower concentration of 20-epi analogues (MC1288 and MC1301) was sufficient to achieve similar growth inhibition. The growth inhibition was associated with a rapid but transient downregulation of IL-1β and IL-1β-converting enzyme (ICE) mRNAs in 1,25D3- and 20-epi analogue-treated cells, and the 20-epi analogue was more effective than 1,25D3 in repressing ICE expression. An examination of long- term changes in the levels of mature IL-1β and its precursor revealed that 24-h incubation of OCIM2 with either 1,25D3 or its 20-epi analogues abolished the production of mature IL-1β. The effect of 1,25D3 and its analogues on growth of fresh bone marrow cells from seven AML patients was tested by a clonogenic assay. Growth inhibition of 60% was reached in only one of seven 1,25D3-treated samples, but all seven samples were inhibited 60-90% by the 20-epi analogue MC1301. Growth inhibition by 1,25D3 and the analogue was reversible by addition of IL-1β. These results suggest that 1,25D3 and its 20-epi analogues interrupt IL-1β autocrine growth regulation by inhibiting IL-1β production and processing but not the response to IL- 1β.
AB - We hypothesized that 1,25-dihydroxyvitamin D3 (1,25D3) and its analogues may inhibit acute myelogenous leukemia (AML) proliferation by interrupting IL-1β-mediated growth-stimulatory signals. The incubation of the IL-1β-responsive AML cell line OCIM2 with 10 nM 1,25D3 reduced growth 80% in liquid culture, and a 100-1000-fold lower concentration of 20-epi analogues (MC1288 and MC1301) was sufficient to achieve similar growth inhibition. The growth inhibition was associated with a rapid but transient downregulation of IL-1β and IL-1β-converting enzyme (ICE) mRNAs in 1,25D3- and 20-epi analogue-treated cells, and the 20-epi analogue was more effective than 1,25D3 in repressing ICE expression. An examination of long- term changes in the levels of mature IL-1β and its precursor revealed that 24-h incubation of OCIM2 with either 1,25D3 or its 20-epi analogues abolished the production of mature IL-1β. The effect of 1,25D3 and its analogues on growth of fresh bone marrow cells from seven AML patients was tested by a clonogenic assay. Growth inhibition of 60% was reached in only one of seven 1,25D3-treated samples, but all seven samples were inhibited 60-90% by the 20-epi analogue MC1301. Growth inhibition by 1,25D3 and the analogue was reversible by addition of IL-1β. These results suggest that 1,25D3 and its 20-epi analogues interrupt IL-1β autocrine growth regulation by inhibiting IL-1β production and processing but not the response to IL- 1β.
KW - 1716-1724 vitamin D
KW - Acute myelogenous leukemia
KW - Analogues
KW - IL-1β
KW - IL-1β-converting enzyme
UR - http://www.scopus.com/inward/record.url?scp=0030930363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030930363&partnerID=8YFLogxK
U2 - 10.1172/JCI119696
DO - 10.1172/JCI119696
M3 - Article
C2 - 9312169
AN - SCOPUS:0030930363
SN - 0021-9738
VL - 100
SP - 1716
EP - 1724
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 7
ER -